日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia

为避免疾病进展和死亡而需要治疗的人数及成本分析:泽布替尼与阿卡替尼治疗复发/难治性慢性淋巴细胞白血病

Shadman, Mazyar; Chanan-Khan, Asher; Campbell, David; Xue, Mei; Massoudi, Marjan; Williams, Rhys; Yang, Keri; Tam, Constantine S

Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience

梅奥诊所基于elotuzumab疗法治疗复发难治性多发性骨髓瘤患者的真实世界疗效:一项经验

Parrondo, Ricardo D; Das, Saurav; Sledge, Hanna; Bergsagel, Leif; Fonseca, Rafael; Leung, Nelson; Kapoor, Prashant; Gertz, Morie; Buadi, Francis; Dispenzieri, Angela; Elliott, Jamie; Fernandez, Andre; Flott, Caitlin; Chanan-Khan, Asher A; Roy, Vivek; Ailawadhi, Sikander

Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia

慢性淋巴细胞白血病中泽布替尼与伊布替尼的治疗所需人数及相关成本分析

Chanan-Khan, Asher; Hanna, Kirollos; Xue, Mei; Massoudi, Marjan; Balk, Mark; Gani, Ray; Piran, Hossein Zivari; Yang, Keri

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

埃洛妥珠单抗联合泊马度胺和地塞米松治疗达雷妥尤单抗难治性多发性骨髓瘤的II期试验

Parrondo, Ricardo D; LaPlant, Betsy R; Elliott, Jamie; Fernandez, Andre; Flott, Caitlin J; Arrington, Diedre; Chapin, Dustin; Brown, Jade; Das, Saurav; Roy, Vivek; Chanan-Khan, Asher A; Ailawadhi, Sikander

Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities

影响多发性骨髓瘤患者接受干细胞移植作为初始治疗的种族因素:探索种族内部医疗保健差异

Ailawadhi, Sikander; Adu, Yaw; Frank, Ryan D; Das, Saurav; Hodge, David O; Fernandez, Andre; Flott, Caitlyn; Elliott, Jamie; Parrondo, Ricardo; Sher, Taimur; Roy, Vivek; Chanan-Khan, Asher A

Mechanistic links between TMEM106B and TDP‐43 dysfunction in AD‐related dementias

TMEM106B 与 TDP-43 功能障碍在阿尔茨海默病相关痴呆症中的机制联系

Manna, Alak; Aulakh, Sonikpreet; Jani, Prachi; Ahmed, Salman; Akhtar, Sharoon; Coignet, Marie; Heckman, Michael; Meghji, Zahara; Bhatia, Kirtipal; Sharma, Aarushi; Sher, Taimur; Alegria, Victoria; Malavasi, Fabio; Chini, Eduardo N; Chanan-Khan, Asher; Ailawadhi, Sikander; Paulus, Aneel; Murray, Melissa E; Dunlop, Sara R; Das, Pritam; Prudencio, Mercedes

MicroRNA and long non-coding RNA analysis in IgM-monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis

IgM单克隆丙种球蛋白病中microRNA和长链非编码RNA的分析揭示了表观遗传对细胞功能和肿瘤发生的影响。

Chohan, Karan; Paludo, Jonas; Dasari, Surendra; Mondello, Patrizia; Novak, Joseph P; Abeykoon, Jithma P; Wenzl, Kerstin; Yang, Zhi-Zhang; Jalali, Shahrzad; Krull, Jordan E; Braggio, Esteban; Manske, Michelle K; Paulus, Aneel; Reeder, Craig B; Ailawadhi, Sikander; Chanan-Khan, Asher; Kapoor, Prashant; Kyle, Robert A; Gertz, Morie A; Novak, Anne J; Ansell, Stephen M

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

Daratumumab、Bortezomib 和 Dexamethasone 治疗既往接受过治疗的多发性骨髓瘤患者的总生存期 (CASTOR):一项随机、开放标签的 III 期试验

Sonneveld, Pieter; Chanan-Khan, Asher; Weisel, Katja; Nooka, Ajay K; Masszi, Tamas; Beksac, Meral; Spicka, Ivan; Hungria, Vania; Munder, Markus; Mateos, Maria-Victoria; Mark, Tomer M; Levin, Mark-David; Ahmadi, Tahamtan; Qin, Xiang; Garvin Mayo, Wendy; Gai, Xue; Carey, Jodi; Carson, Robin; Spencer, Andrew

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

ELEVATE-RR 试验中,acalabrutinib 与 ibrutinib 在既往接受过治疗的慢性淋巴细胞白血病患者中的详细安全性分析

Seymour, John F; Byrd, John C; Ghia, Paolo; Kater, Arnon P; Chanan-Khan, Asher; Furman, Richard R; O'Brien, Susan; Brown, Jennifer R; Munir, Talha; Mato, Anthony; Stilgenbauer, Stephan; Bajwa, Naghmana; Miranda, Paulo; Higgins, Kara; John, Ellie; de Borja, Marianne; Jurczak, Wojciech; Woyach, Jennifer A

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

新型 BCL-2 抑制剂 Lisaftoclax 治疗复发或难治性慢性淋巴细胞白血病及其他血液系统恶性肿瘤:首次人体开放标签试验

Ailawadhi, Sikander; Chen, Zi; Huang, Bo; Paulus, Aneel; Collins, Mary C; Fu, Lei Tommy; Li, Mingyu; Ahmad, Mohammad; Men, Lichuang; Wang, Hengbang; Davids, Matthew S; Liang, Eric; Mekala, Divya J; He, Zhicong; Lasica, Masa; Yannakou, Costas K; Parrondo, Ricardo; Glass, Laura; Yang, Dajun; Chanan-Khan, Asher; Zhai, Yifan